RAPT Therapeutics Inc RAPT.OQ RAPT.O is expected to show no change in quarterly revenue when it reports results on March 5 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for RAPT Therapeutics Inc is for a loss of 37 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for RAPT Therapeutics Inc is $4.00, above its last closing price of $1.14.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.57 | -0.56 | -0.47 | Beat | 16.7 |
Jun. 30 2024 | -0.72 | -0.72 | -0.71 | Beat | 1.4 |
Mar. 31 2024 | -0.80 | -0.81 | -0.79 | Beat | 2.3 |
Dec. 31 2023 | -0.86 | -0.86 | -0.80 | Beat | 6.8 |
Sep. 30 2023 | -0.75 | -0.75 | -0.82 | Missed | -8.9 |
Jun. 30 2023 | -0.79 | -0.78 | -0.66 | Beat | 15.6 |
Mar. 31 2023 | -0.67 | -0.68 | -0.76 | Missed | -11.8 |
Dec. 31 2022 | -0.62 | -0.65 | -0.64 | Beat | 2.1 |
This summary was machine generated March 3 at 13:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。